Clinical trials
T Cells clinical trials
Below are recruiting t cells clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07241585Recruiting
Vitamin D and light therapy for skin cancer
This trial tests whether taking vitamin D before a special light therapy (photodynamic therapy) can help your body fight nonmelanoma skin cancers like basal or squamous cell cancer. You may join if you are scheduled for surgery to remove a skin tumor.
Cleveland, OhioAges 18 years+ - NCT07242547RecruitingPhase 2
Tarlatamab maintenance for limited-stage small cell lung cancer
This trial tests a new immunotherapy medicine called tarlatamab given as maintenance therapy after initial treatment for limited-stage small cell lung cancer. It aims to keep the cancer from coming back.
Albacete, AlbaceteAges 18 years+ - NCT07240610Recruiting
Radiation and immunotherapy for kidney cancer that has spread
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
Chūō, YamanashiAges 18 years+ - NCT07240194RecruitingPhase 2
A study of a new drug combo for large B-cell lymphoma with TP53 changes
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
Nanjing, JiangsuAges 18 years+ - NCT07244419RecruitingEarly Phase 1
Preventing stem cell transplant rejection in children
This early-phase trial tests a medication to prevent rejection of donated stem cells in children. It's for patients who are at high risk for their transplant to fail.
Cincinnati, OhioAges Any age - NCT07244978RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for esophageal cancer
This trial tests whether giving a new immunotherapy drug (ivonescimab) along with standard chemotherapy before surgery can improve outcomes for people with resectable esophageal cancer. The goal is to shrink the tumor and increase the chance of successful surgery.
Hangzhou, ZhejiangAges 18–75 - NCT07240974RecruitingEarly Phase 1
Study of ZZSW-01 for B-cell blood cancers that returned or didn't respond
This trial tests a new drug called ZZSW-01 for people with certain B-cell blood cancers (like lymphoma or leukemia) that have come back or haven't gotten better after other treatments. It aims to see if the drug is safe and works against these cancers.
WuhanAges 18 years+ - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT07240857Enrolling by invitationEarly Phase 1
CAR-T cell injection for advanced prostate cancer
This trial tests a new treatment called ACT#001 CAR-T cells, given as a local injection, for prostate cancer that has stopped responding to hormone therapy. It aims to see if this therapy is safe and can help shrink tumors.
Hangzhou, ZhejiangAges 18 years+ - NCT07249372RecruitingPhase 2
DRP-104 for a specific type of advanced lung cancer
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT07249346RecruitingPhase 2
Preventing GVHD after stem cell transplant with three drugs
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT06735625Recruiting
AHSP as a biomarker for sickle cell disease
This study looks at a substance in the blood called AHSP to see if it can help track sickle cell disease. It compares people with sickle cell disease (SS or Sβ0 type) to people without it, to better understand the condition.
Saint-DenisAges 3 years+ - NCT06896344Recruiting
How cell particles affect blood stem cells in myelofibrosis
This trial is looking at whether tiny particles released by certain cells from people with myelofibrosis can affect their blood-forming stem cells. The goal is to understand the disease better and find new treatments.
Pavia, PaviaAges 18 years+ - NCT06907602RecruitingPhase 2/Phase 3
Optimizing treatment before surgery for advanced esophageal cancer
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04462042Recruiting
Proton vs photon radiation for anal canal cancer
This study compares two types of radiation—protons versus photons—for anal canal squamous cell carcinoma. It may help find which option delivers treatment more effectively or with fewer side effects.
GothenburgAges 18 years+ - NCT05567289Recruiting
Precision medicine after stem cell transplant
This study looks at a personalized (“precision”) approach for people who have received a stem cell transplant from a donor. It may help doctors better tailor care after transplant, especially for children.
ManchesterAges Any age - NCT07232420RecruitingPhase 1
Study of BL-M24D1 for advanced lung cancer and other solid tumors
This trial tests a new drug, BL-M24D1, for people with advanced non-small cell lung cancer or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT07230691Recruiting
Study of amivantamab for advanced EGFR-mutated lung cancer
This study looks at how well a treatment called amivantamab works in people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). It aims to track real-world outcomes in patients who are starting amivantamab for the first time.
GrazAges 18 years+ - NCT07239596RecruitingPhase 1/Phase 2
Study of three drugs for advanced kidney cancer
This trial tests a combination of three drugs (SHR-8068, adebrelimab, and another anti-tumor drug) for people with advanced kidney cancer (clear cell type). The goal is to see if the combination works better than current treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07232524RecruitingPhase 1
BL-M24D1 for advanced head and neck and other solid tumors
This study tests a new drug called BL-M24D1 in people with head and neck cancer or other solid tumors that have spread or cannot be surgically removed. The goal is to see if the drug is safe and can help shrink tumors.
Chengdu, SichuanAges 18 years+ - NCT07231445RecruitingPhase 1
ZG006 with immunotherapy for extensive small cell lung cancer
This trial tests a new drug, ZG006, combined with standard immunotherapy (PD-1/PD-L1 inhibitors) for people with advanced small cell lung cancer that hasn't been treated before. The goal is to find out if this combination works better than the current standard care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07231068RecruitingPhase 1/Phase 2
Dositinib tablets for advanced lung cancer with EGFR mutation
This trial tests a new targeted therapy, Dositinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to earlier EGFR-targeted drugs. It aims to find the best dose and see how well it shrinks tumors.
BeijingAges 18–75 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65
Hear when a new T Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t cells?
- Yes. Clin2 currently lists 5,550 recruiting t cells studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t cells trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t cells trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.